It is well established that overweight and obesity increase a persons risk of cardiovascular events, but the concept of treating obesity to reduce cardiovascular complications has been hampered by lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes, says Dr
14 However, in two studies that included participants not enrolled in the SURPASS and SURMOUNT studies, ie, a large number of individuals who switched from other GLP-1 RAs to tirzepatide, those who transitioned from semaglutide experienced greater weight loss with tirzepatide treatment
The 4.8-star Trustpilot rating across 4,147+ reviews is the strongest on our list by a comfortable margin
Ethics approval Not applicable
Two-thirds of patients drank less on dulaglutide than when they were on placebo (Figure 2B)
Where a batch is published, its Certificate of Analysis appears on this page